Rapport Therapeutics (RAPP) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
UroGen Pharma (URGN) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 6.9% versus a loss of 15.0%. Rapport Therapeutics is the larger company by market cap ($1.37 billion vs $1.36 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RAPP | URGN |
|---|---|---|
| Share price | $23.16 | $27.65 |
| Market cap | $1.37B | $1.36B |
| 1-day change | -1.82% | -12.86% |
| YTD return | -23.67% | +18.06% |
| 1-year return | -15.01% | +6.88% |
| 5-year return | — | +127.76% |
| Forward P/E | — | 11.08 |
| EPS (TTM) | $-3.17 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $-111.48M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $52.93 | $50.81 |
| 52-week low | $22.06 | $16.50 |
| Distance from 52-week high | -56.24% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +177.25% | +119.57% |
| Average volume | 790.62K | 1.11M |
| Shares outstanding | 59.28M | 49.05M |
| Employees | 84 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed RAPP by 21.9 percentage points over the past year.
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
RAPP vs URGN FAQ
Which is bigger, Rapport Therapeutics or UroGen Pharma?
Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.37B compared with $1.36B for UroGen Pharma (URGN).
Which stock has performed better over the past year, RAPP or URGN?
URGN returned +6.88% over the past 12 months, compared with -15.01% for RAPP (price return, excluding dividends). Past performance does not predict future results.
Are Rapport Therapeutics and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.